Načítá se...
Risk of jaw osteonecrosis after intravenous bisphosphonates in cancer patients and patients without cancer
OBJECTIVE: To compare the risk of jaw osteonecrosis after intravenous (IV) bisphosphonate administered to patients with cancer versus to non-cancer patients. PATIENTS AND METHODS: We conducted a retrospective cohort study of a 5% national sample of Medicare patients administered IV bisphosphonate fr...
Uloženo v:
| Vydáno v: | Mayo Clin Proc |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5219844/ https://ncbi.nlm.nih.gov/pubmed/27876314 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.mayocp.2016.09.015 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|